Tectonic Therapeutic to Participate in March Investor Conferences
Tectonic Therapeutic (NASDAQ: TECX), a clinical stage biotech company specializing in therapeutic proteins and antibodies for G-protein coupled receptors (GPCRs), has announced its participation in two investor conferences scheduled for March 2025.
The company will provide live webcasts of both events, accessible through the 'Events & Presentations' section of their website at www.tectonictx.com. Recordings will remain available for approximately 90 days after the conferences conclude.
The management team will conduct one-on-one meetings with investors during both conferences. Interested parties are advised to contact their TD Cowen and/or Leerink representatives to arrange meetings.
Tectonic Therapeutic (NASDAQ: TECX), un'azienda biotecnologica in fase clinica specializzata in proteine terapeutiche e anticorpi per i recettori accoppiati a proteine G (GPCR), ha annunciato la sua partecipazione a due conferenze per investitori programmate per marzo 2025.
L'azienda fornirà webcast dal vivo di entrambi gli eventi, accessibili attraverso la sezione 'Eventi e Presentazioni' del loro sito web all'indirizzo www.tectonictx.com. Le registrazioni rimarranno disponibili per circa 90 giorni dopo la conclusione delle conferenze.
Il team di gestione condurrà incontri individuali con gli investitori durante entrambe le conferenze. Le parti interessate sono invitate a contattare i loro rappresentanti di TD Cowen e/o Leerink per organizzare gli incontri.
Tectonic Therapeutic (NASDAQ: TECX), una empresa biotecnológica en etapa clínica especializada en proteínas terapéuticas y anticuerpos para receptores acoplados a proteínas G (GPCR), ha anunciado su participación en dos conferencias para inversores programadas para marzo de 2025.
La empresa ofrecerá transmisiones en vivo de ambos eventos, accesibles a través de la sección 'Eventos y Presentaciones' de su sitio web en www.tectonictx.com. Las grabaciones estarán disponibles durante aproximadamente 90 días después de que concluyan las conferencias.
El equipo directivo llevará a cabo reuniones uno a uno con los inversores durante ambas conferencias. Se aconseja a las partes interesadas que se pongan en contacto con sus representantes de TD Cowen y/o Leerink para organizar las reuniones.
Tectonic Therapeutic (NASDAQ: TECX), G단백질 결합 수용체(GPCR)를 위한 치료 단백질 및 항체를 전문으로 하는 임상 단계 생명공학 회사가 2025년 3월에 예정된 두 개의 투자자 회의에 참여한다고 발표했습니다.
회사는 www.tectonictx.com의 '이벤트 및 발표' 섹션을 통해 두 이벤트의 라이브 웹캐스트를 제공할 것입니다. 회의 종료 후 약 90일 동안 녹화된 내용이 제공될 예정입니다.
경영진은 두 회의 동안 투자자와 일대일 회의를 진행할 것입니다. 관심 있는 당사자는 회의를 주선하기 위해 TD Cowen 및/또는 Leerink의 담당자에게 연락하시기 바랍니다.
Tectonic Therapeutic (NASDAQ: TECX), une entreprise biopharmaceutique en phase clinique spécialisée dans les protéines thérapeutiques et les anticorps pour les récepteurs couplés aux protéines G (GPCR), a annoncé sa participation à deux conférences pour investisseurs prévues en mars 2025.
L'entreprise proposera des webcasts en direct des deux événements, accessibles via la section 'Événements et Présentations' de leur site web à l'adresse www.tectonictx.com. Les enregistrements resteront disponibles pendant environ 90 jours après la fin des conférences.
L'équipe de direction organisera des réunions individuelles avec les investisseurs lors des deux conférences. Les parties intéressées sont invitées à contacter leurs représentants de TD Cowen et/ou Leerink pour organiser des réunions.
Tectonic Therapeutic (NASDAQ: TECX), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf therapeutische Proteine und Antikörper für G-Protein-gekoppelte Rezeptoren (GPCRs) spezialisiert hat, hat seine Teilnahme an zwei Investorenkonferenzen angekündigt, die für März 2025 geplant sind.
Das Unternehmen wird Live-Webcasts beider Veranstaltungen anbieten, die über den Bereich 'Veranstaltungen & Präsentationen' auf ihrer Website www.tectonictx.com zugänglich sind. Aufzeichnungen werden etwa 90 Tage nach Abschluss der Konferenzen verfügbar bleiben.
Das Management-Team wird während beider Konferenzen Einzelgespräche mit Investoren führen. Interessierte Parteien werden gebeten, ihre Vertreter von TD Cowen und/oder Leerink zu kontaktieren, um Treffen zu vereinbaren.
- None.
- None.
WATERTOWN, Mass., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced that company management will participate in two upcoming investor conferences taking place in March 2025.
| TD Cowen 45th Annual Health Care Conference | |
| Date: | March 5, 2025 |
| Time: | 9:50 AM EST |
| Location: | Boston, MA |
| Format: | Corporate Presentation |
| Presenter: | Alise Reicin, MD, President and Chief Executive Officer |
| Webcast: | Link |
| Leerink Partners Global Healthcare Conference | |
| Date: | March 11, 2025 |
| Time: | 11:20 AM EDT |
| Location: | Miami, FL |
| Format: | Fireside Chat |
| Presenters: | Daniel Lochner, Chief Financial Officer, and Marc Schwabish, PhD, Chief Business Officer |
| Webcast: | Link |
Both live webcasts can also be accessed under “Events & Presentations” on the Investors section of the Tectonic website at www.tectonictx.com. Once these conferences have concluded, a replay of the two webcasts will be available on the Company’s website for approximately 90 days.
The Tectonic management team will host one-on-one meetings during both conferences. Interested investors should contact their TD Cowen and/or Leerink representative to schedule meetings.
About Tectonic
Tectonic is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (“GPCRs”). Leveraging its proprietary technology platform called GEODe™ (GPCRs Engineered for Optimal Discovery), Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery and harness the human body to modify the course of disease. Tectonic focuses on areas of significant unmet medical need, often where therapeutic options are poor or nonexistent, as these are areas where new medicines have the potential to improve patient quality of life. Tectonic is headquartered in Watertown, Massachusetts. For more information, please visit www.tectonictx.com and follow on LinkedIn.
FAQ
When will Tectonic Therapeutic (TECX) participate in the March 2025 investor conferences?
How long will the TECX March 2025 conference webcasts be available for replay?
How can investors access Tectonic Therapeutic's March 2025 conference webcasts?
How can investors schedule one-on-one meetings with TECX management during the March 2025 conferences?
What is Tectonic Therapeutic's (TECX) primary research focus?
